(Z)-Rose oxide is a trace-to-minor monoterpene ether best known for delivering a powerful rosy-green accent in rose, geranium, lychee, and related floral-fruity profiles. The live evidence base is unusually better than for many niche aroma constituents: public identity sources support its stereochemical assignment, and preclinical papers report anti-inflammatory, antidepressant-like, and cardiovascular effects in rodent models. Those findings are still early-stage pharmacology rather than human outcome evidence, so archive copy should frame rose oxide as an odor-active constituent with promising but preclinical bioactivity data.
Chemical identity and composition
PubChem and The Good Scents Company both identify the Z isomer as 4-methyl-2-(2-methylprop-1-enyl)oxane with formula C10H18O. In perfumery and flavor contexts, the cis/Z form is the better-known rosy-green impact material, and archive oil context places it in Chinese geranium profiles as a supporting rose-like note rather than a bulk constituent.
Aroma and practical use
- Use the recorded rosy, green, fresh, geranium-like, lychee-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 rodent study found that rose oxide reduced CFA- and carrageenan-linked edema, lowered carrageenan myeloperoxidase activity, decreased leukocyte migration, and reduced local IL-1beta production in the CFA model.
A 2012 rodent study found that rose oxide reduced CFA- and carrageenan-linked edema, lowered carrageenan myeloperoxidase activity, decreased leukocyte migration, and reduced local IL-1beta production in the CFA model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
A 2021 behavioral paper reported that 50 mg/kg rose oxide lowered immobility in forced-swim and tail-suspension tests without changing open-field or rota-rod performance, supporting an antidepressant-like signal in mice.
A 2021 behavioral paper reported that 50 mg/kg rose oxide lowered immobility in forced-swim and tail-suspension tests without changing open-field or rota-rod performance, supporting an antidepressant-like signal in mice.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
A 2021 cardiovascular study reported that intravenous rose oxide lowered mean arterial pressure in spontaneously hypertensive rats, attenuated low-frequency systolic-pressure variability, and relaxed aortic rings ex vivo.
A 2021 cardiovascular study reported that intravenous rose oxide lowered mean arterial pressure in spontaneously hypertensive rats, attenuated low-frequency systolic-pressure variability, and relaxed aortic rings ex vivo.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe accessible efficacy literature for isolated rose oxide is preclinical only; those findings should not be translated into medical treatment claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
This pass did not verify a constituent-specific human dermal limit, IFRA-style finished-product limit, or human clinical safety trial for isolated (Z)-rose oxide.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
reduced IL-1beta production and leukocyte migration in inflammatory models
The 2012 anti-inflammatory study linked rose oxide activity to lower IL-1beta production and reduced inflammatory-cell migration rather than broad suppression of every cytokine measured.
This experimental finding does not establish benefit, dose or safety in people using this blend.
possible serotonergic-pathway interaction
The 2021 antidepressant-like paper paired behavioral effects with docking-based support for serotonergic receptor interactions, which is suggestive rather than definitive target validation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
autonomic and vasorelaxant effects in hypertensive-rat models
The cardiovascular paper reported hypotension, bradycardia, and vasorelaxant effects in spontaneously hypertensive rats, with hexamethonium sensitivity suggesting autonomic involvement.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a human clinical trial for isolated (Z)-rose oxide.
- Publicly accessible safety data were much thinner than the preclinical pharmacology abstracts.
- Many published sources discuss rose oxide generically or as mixed stereoisomers, so some identity language in the broader literature is not Z-isomer-specific.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.